Sign In
Buy CNTB
$2.02
-0.0700 (-3.35%)
At Close: Jul 31, 2026
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
09:00am, Wednesday, 13'th Aug 2025
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations – – Presented positive data at ATS 2025 and EAACI 2025 supporti
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now?
01:00pm, Wednesday, 30'th Jul 2025
Does Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Connect Biopharma Appoints Industry Veteran Jim Schoeneck to its Board of Directors
09:00am, Tuesday, 22'nd Jul 2025
– Mr. Schoeneck is a seasoned industry executive and director with deep expertise in development and commercialization of breakthrough products and guiding companies through significant transformati
SAN DIEGO, July 21, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on tra
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference
09:00am, Friday, 18'th Jul 2025
SAN DIEGO, July 18, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma”, “Connect”, or the “Company”), a clinical-stage biopharmaceutical compan
Connect Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
09:00am, Thursday, 17'th Jul 2025
SAN DIEGO, July 17, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on tra
– Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma –
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on tra
Connect Biopharma to Present at Two Upcoming Investor Conferences in June
09:00am, Wednesday, 28'th May 2025
SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a clinical-stage biopharmaceutical company focused on tran
– Rademikibart significantly improved airway function, as measured by FEV 1 , within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongl
Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
09:00am, Thursday, 15'th May 2025
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in
Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
09:00am, Wednesday, 14'th May 2025
– Expect to report topline data from the Seabreeze STAT COPD study in 1H 2026 – SAN DIEGO, May 14, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Co
– Expect to report topline data from the Seabreeze STAT Asthma study in 1H 2026 – – On track to initiate similarly-designed Phase 2 study in patients with COPD imminently – SAN DIEGO, May 13,
Connect Biopharma Announces Multiple Presentations at the American Thoracic Society (ATS) 2025 International Conference
09:00am, Thursday, 24'th Apr 2025
– Data to be presented supports development of rademikibart for patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Advancing rapid clinical development plan f
Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart
09:00am, Tuesday, 01'st Apr 2025
– FDA aligned on plan to initiate parallel Phase 2 trials of rademikibart in patients with moderate-to-severe asthma or COPD experiencing an acute exacerbation – – Expect to initiate both trial
